Business News, In Brief
Executive Summary
Celgene ups 2010 guidance; Revlimid drives growth: Celgene increased its guidance for the year, with total revenues expected to grow about 25 percent year-over-year to $3.3 billion-$3.4 billion, up from a previous range of $3.2 billion-$3.3 billion, execs said during a first quarter earnings call April 29. The biopharma also expects sales of the cancer product Revlimid (lenalidomide) to grow 30 percent year-over-year, ranging from $2.2 billion-$2.3 billion. Leerink Swann analysts seemed encouraged by Revlimid's growth potential. "We believe the presentations of the CALGB-100104 and IFM-05-02 trials on maintenance in the post-stem cell transplant setting" at the ASCO annual scientific meeting "could be important catalysts for adoption of Revlimid in this setting," they said in a same day note. "A previous MEDACorp survey following the release of the CALGB data in late December 2009 showed that 89 percent (33 of 37) of hematologists/oncologists surveyed indicated they would increase their use of Revlimid in this setting as a result of the trial," they added. For the quarter, Revlimid brought in global sales of $530.5 million, up 46 percent
You may also be interested in...
Vyvanse Adds 14-Hour Duration Data As Shire's ADHD Drugs Face Off With Generics
Duration of use data will help to strengthen Vyvanse's position in the fast-growing adult segment, Shire says.
PAH Market Heats Up: New Approvals For Actelion, United Therapeutics
With a Risk Evaluation and Mitigation Strategy for Tracleer now approved by FDA, Actelion can maximize the drug's selling potential across a broader range of pulmonary arterial hypertension patients before it faces generics in 2015
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011